COMMON QUESTIONS · CITED ANSWERS
PT-141: the questions people actually ask
Direct answers on bremelanotide, cited to the literature, with the off-label boundary stated plainly.
What does the PT-141 peptide do?
PT-141 switches on melanocortin receptors (MC3R/MC4R) in the brain, which nudges the circuits that drive sexual desire [1][12]. In animals it produced erections and activated hypothalamic neurons; in men with erectile dysfunction it produced rapid, dose-dependent erectile activity [1]. It works on desire and arousal centrally, not on blood vessels.
How does PT-141 work?
PT-141 is a synthetic copy of the brain peptide alpha-MSH. It docks onto melanocortin receptors — mainly MC4R — in the hypothalamus and switches them on [1][12]. That is thought to engage dopamine pathways tied to sexual motivation [1]. Human brain imaging confirms a central effect: MC4R agonism raised desire for up to 24 hours [5].
What receptors does PT-141 act on?
PT-141 is an agonist (an activator) at the melanocortin 4 and 3 receptors — MC4R and MC3R — which sit mainly in the central nervous system [1][12]. MC4R is the main target for the desire effect. It also reaches MC1R on pigment cells, which explains the skin-darkening reported with frequent dosing [7].
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 acts centrally on melanocortin receptors, not on peripheral blood vessels [1][12]. This was tested directly: in rabbit tissue, natural alpha-MSH relaxed vaginal-wall and artery preparations but bremelanotide (1 µM) did not, consistent with a central rather than a local vascular mechanism [8].
What is a melanocortin receptor agonist?
A melanocortin receptor agonist is a molecule that switches on melanocortin receptors — a family of five brain-and-body switches (MC1R–MC5R) that respond to natural peptides like alpha-MSH [1]. PT-141 is one such agonist, acting chiefly at the central MC4R and MC3R subtypes [12].
Does PT-141 increase testosterone?
No. PT-141 does not act through the testosterone (HPG) axis and does not directly raise testosterone [1][12]. This is a common misconception. It works on central melanocortin receptors that influence sexual desire — a different system entirely from the hormones that regulate testosterone production.
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors act peripherally on blood-vessel smooth muscle to improve erectile blood flow. PT-141 acts centrally, in the brain, on melanocortin receptors that influence sexual desire [1][12]. The mechanisms are unrelated: one is a vascular drug, the other a central neuromodulator, confirmed by tissue studies showing no direct vascular relaxation [8].
Why does PT-141 cause nausea?
Nausea is the most common side effect — 40.4% in long-term use [4]. It is tied to central melanocortin signaling, the same brain-level activity that produces the desired effect. In the trials it was the principal tolerability problem and a notable reason people discontinued [4]; injection timing and dose strategy have been studied as mitigations.
Does PT-141 cause skin darkening or hyperpigmentation?
It can with repeated frequent dosing. Hyperpigmentation of the face, gums, and breasts is reported and is attributed to activation of MC1R, a melanocortin receptor on pigment cells [7]. Because PT-141 activates melanocortin receptors broadly, it can reach the pigment system as well as the brain circuits it is intended for.
Does PT-141 cause weight loss?
Weight and appetite effects appeared only in high-frequency experimental dosing, not in approved use, and reflect MC4R's role in appetite circuits [7]. This is a pharmacological consideration, not an approved or established use. PT-141 is not a weight-loss drug, and no trial supports using it for that purpose.
What is PT-141?
PT-141 is a synthetic cyclic heptapeptide — a seven-amino-acid ring — that copies the natural brain peptide alpha-MSH and switches on central melanocortin receptors [1]. Its formal name is bremelanotide. It is FDA-approved for one use: HSDD in premenopausal women [7].
What is PT-141 peptide?
PT-141 peptide is the same molecule as bremelanotide — a melanocortin receptor agonist built as an analogue of alpha-MSH [1]. "Peptide" simply means it is a short chain of amino acids. Material sold under the "PT-141 peptide" label as a research chemical is unregulated for identity and purity [7].
What is PT-141 used for?
Its one approved use is treating hypoactive sexual desire disorder (HSDD) in premenopausal women [3][7]. It is widely promoted off-label for men, postmenopausal women, and sexual performance, but those uses are not approved and rest on thinner evidence [7][11].
Is PT-141 the same as bremelanotide?
Yes. "PT-141" is the developmental code name and "bremelanotide" is the international nonproprietary name (INN) for the identical molecule [1]. The research-chemical "PT-141" form sits outside the pharmaceutical approval framework that governs the approved bremelanotide product [7].
What is bremelanotide?
Bremelanotide is the formal name for PT-141 — a melanocortin receptor agonist approved in 2019 (NDA 210557) for HSDD in premenopausal women [7]. It is a synthetic cyclic heptapeptide analogue of alpha-MSH that acts centrally on MC4R and MC3R [1][12].
What is the PT-141 dosage?
The approved label dose is 1.75 mg subcutaneously, as needed, with a maximum of one dose per 24 hours and no more than eight per month, for HSDD in premenopausal women [7]. This is a documented label figure, not a recommendation, and it does not transfer to any off-label use [7].
How much PT-141 should I take?
This site does not recommend a dose. The only established figure is the approved label dose of 1.75 mg subcutaneous, as needed, for premenopausal women with HSDD [7]. For any off-label setting, or for unregulated "research chemical" material, there is no established dose because there is no supporting evidence base [7].
How much PT-141 to inject?
The approved label specifies 1.75 mg subcutaneously for the approved indication, with strict frequency limits [7]. We report that figure as documentation only and do not advise any injection for anyone. Unregulated material has no verified concentration, making any injected amount uncertain by definition [7].
What is the PT-141 dosage for women?
In premenopausal women with HSDD, the approved and trial dose is 1.75 mg subcutaneous, as needed [3][7]. Phase 2 dose-finding in women tested 0.75, 1.25, and 1.75 mg [7]. In female-rat models, PT-141 selectively increased desire-driven behavior without affecting reflexes or movement — a preclinical mechanism finding, not a human dose [2].
How do you reconstitute PT-141?
The approved bremelanotide product is supplied as a ready-to-use prefilled formulation, not a powder the user mixes, per the prescribing information [7]. "Reconstitution" questions arise around unregulated research-chemical powders, which have no verified strength or purity and no approved preparation method [7]. This site reports the label, not a preparation procedure.
How do you take PT-141?
In approved use, bremelanotide is given as a subcutaneous (under-the-skin) injection, as needed, at least 45 minutes before anticipated activity, within strict frequency limits [7]. We describe the documented route, not an instruction to use it. Off-label and research-chemical use lacks any equivalent evidence or guidance [7].
How often can you take PT-141?
The approved label caps dosing at one dose per 24 hours and no more than eight doses per month [7]. In the 52-week extension of RECONNECT, this as-needed pattern was sustained without new safety signals, though nausea (40.4%) remained the main tolerability issue [4]. This is a documented limit, not a recommendation.